Piper Sandler Downgrades Mesoblast to Neutral, Lowers Price Target to $2
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Edward Tenthoff has downgraded Mesoblast (NASDAQ:MESO) from Overweight to Neutral and lowered the price target from $7 to $2.
August 04, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mesoblast's rating has been downgraded by Piper Sandler from Overweight to Neutral, with a reduced price target of $2.
The downgrade from Piper Sandler is likely to negatively impact Mesoblast's stock in the short term. The lowered price target from $7 to $2 indicates a significant decrease in the expected value of the stock, which could lead to selling pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100